undamentalytics Newsletter
Sign in

Hyperfine, Inc. (HYPR) stock

Add to watchlist

Add holding +

NASDAQ: HYPR Nasdaq Health Care Equipment Next results ~November 9, 2026

C Fundamentals grade

Hyperfine, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.2

Price-to-sales vs peers

Base case. Range ~$0.2–$0.8. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Hyperfine, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds54 adding, 15 cuttingOf 11 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Hyperfine files

Where Hyperfine stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $17m, up 53.2% on a year earlier, faster than the 30.7% growth a quarter earlier. That growth ranks 7 of 103 among the health care equipment companies we cover. Free-cash-flow margin rose to -166.5% from -325.9% a year earlier. Operating margin widened to -203.3% from -391.1%. The diluted share count is up 23.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 5 of our 6 financial-health checks. Our price-to-sales vs peers value is $0.16 a share, against a share price of $0.75.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Hyperfine, Inc.'s trailing-twelve-month revenue grew 53.2% year on year, with a free-cash-flow margin of -166.5%. Where it stands out: change in growth rate of +22.5pp ranks 8 of 129 health care equipment companies we cover. Where it lags: days sales outstanding of 93 days ranks 106 of 118 health care equipment companies we cover.

Current signal Operating margin expanding: TTM operating margin reached -203.3%, up 187.8pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 53.2% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Growth speeding up. The growth rate is 22.5 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 187.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -203.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -166.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 17.3% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 23.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 71% and a beta of 2.0 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 93 days ranks 106 of 118 health care equipment companies we cover (median 57 days).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.09 against an average estimate of -$0.09: beat by 0.0%
Revenue
$4m, up 44.8% on a year earlier
Share reaction
+9.7% in the first session after the results on October 8, 2026, against +0.2% for the S&P 500
Guidance given
revenue $20m to $22m (full year 2026); net cash burn, excluding financing proceeds $26m to $28m (full year 2026)
Next report
November 9, 2026; average EPS estimate -$0.08

Hyperfine's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.0%
  • 1 week+0.3%
  • 1 month-18.9%
  • This year-25.9%
  • 1 year-35.3%
  • 5 years-92.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$16.5M
Operating margin
-203.3%
Net margin
-210.8%
EPS (TTM, diluted)
$-0.38

Growth

Revenue growth
+53.2%
Change in growth rate
+22.5 pts
Share count change
+23.9%

Cash

Free cash flow (TTM)
-$27.5M
FCF margin
-166.5%
Stock pay % of revenue
17.3%

Earnings

Last results
October 8, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Hyperfine, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Hyperfine, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.2–$0.8 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.2 ~$0.2–$0.8 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Hyperfine, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$7.25$0.84$1.12$0.88$0.98$0.72
Market value$535m$59m$80m$64m$80m$67m
+ Net debt (− = net cash)−$188m−$117m−$75m−$38m−$35m−$30m
Enterprise value$347m−$58m$5m$26m$45m$37m
Multiples
Price / sales n/m8.7x7.2x4.9x5.9x4.1x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

22 /100

Weak moat

How hard Hyperfine's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -55.3% of total assets over 5 years.

  • Pricing power 7 / 20

    Gross margin has been a median 44.5%, moving by 27.3 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -391.1%; its worst year was -2323.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -345.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $6m and EPS of −$0.08 (range −$0.09 to −$0.08) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.34 +23% $21m +52%
Next −$0.32 +8% $27m +31%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.5% on 90 days ago. In the last 30 days, 1 analyst raised Hyperfine, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Hyperfine, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.34 Current fiscal year, 60 days ago: −$0.34 Current fiscal year, 30 days ago: −$0.34 Current fiscal year, 7 days ago: −$0.34 Current fiscal year, Now: −$0.34 −$0.34 Next fiscal year, 90 days ago: −$0.34 Next fiscal year, 60 days ago: −$0.32 Next fiscal year, 30 days ago: −$0.32 Next fiscal year, 7 days ago: −$0.32 Next fiscal year, Now: −$0.32 −$0.32

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.34−$0.34
60 days ago −$0.34−$0.32
30 days ago −$0.34−$0.32
7 days ago −$0.34−$0.32
Now −$0.34−$0.32

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.09 −$0.09 0.0%
Dec 2025 −$0.08 −$0.08 +2.1%
Sept 2025 −$0.10 −$0.14 −33.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 8, 2026
  • revenue full year 2026 $20m to $22m Maintained
    “Management continues to expect revenue for the full year 2026 to be approximately $20 to $22 million, representing 55% growth at the midpoint as compared to full year 2025.” source
  • net cash burn, excluding financing proceeds full year 2026 $26m to $28m Non-GAAP Maintained
    “Management continues to expect net cash burn, excluding financing proceeds, for the full year 2026 to be approximately $26 to $28 million 1 , representing a 10% decline at the midpoint as compared to full year 2025.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202633
  3. Aug 202633
  4. Jul 202633

Counts of recommendations published by analysts covering Hyperfine, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.3%
of tradable shares
Days to cover
3.29
at average volume
Short interest, 1 month
−11%
to October 15, 2026
Held by institutions
23%
of shares
Held by insiders
4.4%
of shares
Employees
102
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −35.3%

$1.12 on October 31, 2025 to $0.72

ThenNowEffect
Revenue (last 12 months) $11m $17m +53.2%
P/S multiple 7.8x 4.1x −47.7%
Share count 75m 93m −19.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −46.3%

$1.35 on November 3, 2023 to $0.72

ThenNowEffect
Revenue (last 12 months) $10m $17m +69.0%
P/S multiple 9.8x 4.1x −58.4%
Share count 71m 93m −23.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
HYPR−88%+33%−21%+11%−26%
Industry peers (median)−37%−9%−19%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
HYPR25%50%50%50%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
HYPR−90%−68%−37%−68%−62%
S&P 500−25%−10%−8%−19%−9%

Worst fall since January 28, 2021: 95% from December 22, 2021 to May 23, 2025. Getting back needed a 1904% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.72 – $1.87
From 52-week high
−61.2%
vs 50-day average
−10.4%
vs 200-day average
−35.7%
Volatility (1 year)
71%
Beta vs S&P 500
1.99

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±12.2%
After a week
2 up, 10 down
typical move ±14.9%
After a month
5 up, 6 down
typical move ±19.1%
Results releasedNext dayS&P 500 next day5 days21 days
October 8, 2026 +9.7% +0.2% −8.1% —
August 6, 2026 −2.6% +0.5% −8.9% −17.0%
May 12, 2026 −9.1% +0.4% −19.4% −18.9%
March 18, 2026 −6.9% −1.6% −10.0% +0.8%
January 12, 2026 +12.9% 0.0% +18.8% +8.9%
November 13, 2025 +4.5% −1.7% −6.8% −15.6%
October 15, 2025 −30.7% −0.2% −40.0% −48.8%
August 13, 2025 +20.8% +0.4% +6.7% +18.3%
May 13, 2025 −16.0% +0.8% −14.8% +1.5%
March 17, 2025 −0.8% −0.3% −9.7% −23.9%
February 11, 2025 −28.1% −0.2% −31.7% −44.9%
November 12, 2024 −4.0% −0.3% −3.5% +12.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Hyperfine, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Hyperfine, Inc.
$8M $10M $12M $14M $16M $18M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $9.8M Revenue (TTM), FY23 Q4: $11M Revenue (TTM), FY24 Q1: $11.7M Revenue (TTM), FY24 Q2: $11.9M Revenue (TTM), FY24 Q3: $13.3M Revenue (TTM), FY24 Q4: $12.9M Revenue (TTM), FY25 Q1: $11.7M Revenue (TTM), FY25 Q2: $10.8M Revenue (TTM), FY25 Q3: $10.6M Revenue (TTM), FY25 Q4: $13.6M Revenue (TTM), FY26 Q1: $15.3M Revenue (TTM), FY26 Q2: $16.5M $16.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $9.8M
FY23 Q4 $11M
FY24 Q1 $11.7M
FY24 Q2 $11.9M
FY24 Q3 $13.3M
FY24 Q4 $12.9M
FY25 Q1 $11.7M
FY25 Q2 $10.8M
FY25 Q3 $10.6M
FY25 Q4 $13.6M
FY26 Q1 $15.3M
FY26 Q2 $16.5M
Revenue growth, TTM YoY Hyperfine, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 67.7% Revenue growth, TTM YoY, FY23 Q4: 61.9% Revenue growth, TTM YoY, FY24 Q1: 47.3% Revenue growth, TTM YoY, FY24 Q2: 22.0% Revenue growth, TTM YoY, FY24 Q3: 35.7% Revenue growth, TTM YoY, FY24 Q4: 16.8% Revenue growth, TTM YoY, FY25 Q1: 0.3% Revenue growth, TTM YoY, FY25 Q2: -9.6% Revenue growth, TTM YoY, FY25 Q3: -20.1% Revenue growth, TTM YoY, FY25 Q4: 5.2% Revenue growth, TTM YoY, FY26 Q1: 30.7% Revenue growth, TTM YoY, FY26 Q2: 53.2% 53.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 67.7%
FY23 Q4 61.9%
FY24 Q1 47.3%
FY24 Q2 22.0%
FY24 Q3 35.7%
FY24 Q4 16.8%
FY25 Q1 0.3%
FY25 Q2 -9.6%
FY25 Q3 -20.1%
FY25 Q4 5.2%
FY26 Q1 30.7%
FY26 Q2 53.2%
Operating margin (TTM) Hyperfine, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -512.9% Operating margin (TTM), FY23 Q4: -436.1% Operating margin (TTM), FY24 Q1: -391.1% Operating margin (TTM), FY24 Q2: -375.8% Operating margin (TTM), FY24 Q3: -332.6% Operating margin (TTM), FY24 Q4: -335.3% Operating margin (TTM), FY25 Q1: -370.6% Operating margin (TTM), FY25 Q2: -391.1% Operating margin (TTM), FY25 Q3: -379.4% Operating margin (TTM), FY25 Q4: -273.4% Operating margin (TTM), FY26 Q1: -226.6% Operating margin (TTM), FY26 Q2: -203.3% -203.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -512.9%
FY23 Q4 -436.1%
FY24 Q1 -391.1%
FY24 Q2 -375.8%
FY24 Q3 -332.6%
FY24 Q4 -335.3%
FY25 Q1 -370.6%
FY25 Q2 -391.1%
FY25 Q3 -379.4%
FY25 Q4 -273.4%
FY26 Q1 -226.6%
FY26 Q2 -203.3%
FCF margin (TTM) Hyperfine, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -490.5% FCF margin (TTM), FY23 Q4: -386.3% FCF margin (TTM), FY24 Q1: -356.8% FCF margin (TTM), FY24 Q2: -345.7% FCF margin (TTM), FY24 Q3: -309.2% FCF margin (TTM), FY24 Q4: -303.7% FCF margin (TTM), FY25 Q1: -308.7% FCF margin (TTM), FY25 Q2: -325.9% FCF margin (TTM), FY25 Q3: -304.3% FCF margin (TTM), FY25 Q4: -214.8% FCF margin (TTM), FY26 Q1: -187.0% FCF margin (TTM), FY26 Q2: -166.5% -166.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -490.5%
FY23 Q4 -386.3%
FY24 Q1 -356.8%
FY24 Q2 -345.7%
FY24 Q3 -309.2%
FY24 Q4 -303.7%
FY25 Q1 -308.7%
FY25 Q2 -325.9%
FY25 Q3 -304.3%
FY25 Q4 -214.8%
FY26 Q1 -187.0%
FY26 Q2 -166.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 7 11 13 14 17
Gross profit −0 −1 1 5 6 7 9
EBITDA −23 −64 −73 −47 −42 −36 −32
Operating income −23 −65 −74 −48 −43 −37 −34
Net income −23 −65 −44 −44 −41 −36 −35
Diluted EPS −$0.77 −$0.88 −$1.04 −$0.62 −$0.56 −$0.43 −$0.38
Growth (year on year)
Revenue — +408.8% +355.5% +61.9% +16.8% +5.2% +53.2%
Margins
Gross margin −162.2% −78.0% 13.3% 43.1% 45.7% 49.8% 51.4%
EBITDA margin <−999% <−999% <−999% −426.6% −327.5% −265.4% −196.5%
Operating margin <−999% <−999% <−999% −436.1% −335.3% −273.4% −203.3%
Net margin <−999% <−999% −649.2% −401.0% −315.9% −262.3% −210.8%
Free-cash-flow margin <−999% <−999% <−999% −386.3% −303.7% −214.8% −166.5%
Cash flow
Cash from operations −22 −47 −72 −42 −39 −28 −27
Capital spending 2 3 1 1 0 1 0
Free cash flow −23 −50 −73 −43 −39 −29 −28
Stock-based pay 1 7 11 5 4 3 3
Free cash flow after stock pay −24 −57 −84 −47 −44 −32 −30
Balance sheet
Cash 63 188 117 75 38 35 43
Total debt 0 — 0 0 0 0 13
Net debt (negative = net cash) −62 −188 −117 −75 −38 −35 −30
Diluted shares 30m 74m 70m 71m 72m 82m 93m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 6 checks passed · June 30, 2026
What it owns · $63m
Short-term assets $59mLonger-term assets $4m
What it owes, and who funded it · $63m
Short-term liabilities $10mLonger-term liabilities $17mShareholders' equity $37m
  • Short-term assets cover short-term liabilities $59m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $59m short-term assets against $17m of longer-dated liabilities.
  • More cash than debt $43m of cash against $13m of debt.
  • Debt below 40% of shareholders' equity Debt is 36% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$27m of operating cash flow against $13m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Hyperfine, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+23.9%
year over year
R&D spending
94.2%
of revenue
Days sales outstanding
93 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated HYPR SRTS MDAI ZJYL NEPH VVOS Median
Revenue, last 12 months $17m $18m $15m $21m $21m $21m $99m
Revenue growth, last 12 months 53.2% −53.4% −44.1% −12.0% 24.2% 45.2% 9.2%
Revenue growth, 3-year average 19.1% −16.5% −11.8% — 19.3% 10.6% 13.5%
Revenue growth, latest quarter 44.8% −68.7% −30.4% — 36.2% 34.9% 10.2%
Gross margin 51.4% 36.4% 42.9% 29.2% 61.3% 61.9% 61.2%
Operating margin −203.3% −75.7% −77.2% 2.9% 7.9% −107.9% −8.5%
Operating margin, 3-year average −323.4% −18.6% −49.1% — 2.0% −101.0% −17.9%
Net margin −210.8% −88.5% −65.5% 5.8% 8.4% −121.8% −12.0%
Cash from operations / revenue −163.7% −38.8% −83.7% 14.0% −3.4% −82.0% −1.9%
Free-cash-flow margin −166.5% −39.8% −84.4% −18.0% −4.0% −91.0% −3.9%
Free-cash-flow margin, 3-year average −279.4% −11.2% −58.8% — −0.1% −94.3% −7.0%
Stock pay / revenue 17.3% 1.2% 10.0% — 1.3% 1.9% 6.1%
Change in share count 23.9% 0.2% 38.4% 0.0% 4.0% 20.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 53.2% 9.1% 11 of 129
Change in growth rate Growth +22.5pp -0.6pp 8 of 129
Gross margin Profitability 51.4% 61.9% 85 of 123
Operating margin Profitability -203.3% -8.3% 109 of 132
Net margin Profitability -210.8% -12.0% 110 of 133
Free-cash-flow margin Cash generation -166.5% -3.4% 107 of 128
Stock pay as % of revenue Cash generation 17.3% 6.1% 94 of 123
Long-term debt as % of assets Balance sheet 21.0% 24.2% 41 of 87
Change in share count Balance sheet 23.9% 3.3% 93 of 115
Days sales outstanding Balance sheet 93 days 57 days 106 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $11.4M 84.0% ▲ 9.1%
Services $2.2M 16.0% ▼ 11.3%

From Hyperfine, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$29.4M
Institutions reporting
81
Shares held vs prior quarter
▲ 56.1%
Positions opened / closed
38 / 7

Top buyers and sellers, Q2 2026: 54 institutions bought and 15 sold ; the biggest buyer was Blackrock, Inc (+4.1M shares) and the biggest seller Sio Capital Management, LLC (−1.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $6.3M 4.7M 21.4% ▲ 712.8%
Vanguard Capital Management LLC $4.6M 3.4M 15.5% ▼ 2.1%
Geode Capital Management, LLC $2.6M 2.0M 9.0% ▲ 105.3%
Fosun International Ltd $2.4M 1.7M 8.0% 0.0%
Catalio Capital Management, LP $1.8M 1.3M 6.1% 0.0%
State Street Corp $1.4M 1.0M 4.7% ▲ 213.8%
Renaissance Technologies LLC $1.3M 946K 4.3% ▲ 29.5%
Alphabet Inc. $1.2M 899K 4.1% 0.0%
Northern Trust Corp $854,623 633K 2.9% ▲ 256.9%
Vanguard Fiduciary Trust Co $765,597 567K 2.6% ▲ 7.7%
Vanguard Portfolio Management LLC $738,720 547K 2.5% New
HRT Financial LP $505,000 374K 1.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Hyperfine, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $93,405 8 trades by 2 insiders · 0% under pre-set plans
Net ▼ $93,405 net selling
Insider Date Trade Shares Price Value
Hale Brett CFO and CAO August 24, 2026 Sell 7,345 $0.85 $6,243
Teisseyre Thomas Chief Operating Officer August 24, 2026 Sell 7,345 $0.85 $6,243
Teisseyre Thomas Chief Operating Officer May 26, 2026 Sell 6,047 $1.65 $9,978
Hale Brett CFO and CAO May 26, 2026 Sell 6,047 $1.65 $9,978
Hale Brett CFO and CAO March 23, 2026 Sell 24,188 $1.21 $29,267
Teisseyre Thomas Chief Operating Officer March 23, 2026 Sell 24,188 $1.21 $29,267
Teisseyre Thomas Chief Operating Officer February 13, 2026 Sell 821 $1.11 $911
Teisseyre Thomas Chief Operating Officer November 19, 2025 Sell 1,405 $1.08 $1,517

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 8, 2026
  • August 6, 2026
  • May 12, 2026
  • March 18, 2026
  • January 12, 2026
  • November 13, 2025

Recent SEC filings

Data status

When each part of this page on Hyperfine, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Hyperfine, Inc. in brief

What does Hyperfine, Inc. do?
Hyperfine, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Hyperfine, Inc.'s stock ticker?
Hyperfine, Inc. trades under the ticker HYPR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Hyperfine, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Hyperfine, Inc. reported revenue of $16.5M, 53.2% higher than a year earlier, according to its SEC filings.
What is Hyperfine, Inc.'s free cash flow?
Hyperfine, Inc.'s free-cash-flow margin is -166.5% of revenue over the trailing twelve months, ranking 107 of the 128 health care equipment companies we cover.
Who are Hyperfine, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Hyperfine, Inc.'s market cap?
On November 2, 2026, Hyperfine, Inc.'s market capitalisation was about $67.2M and net debt of -$30.2M. Market figures come from third-party market data and may be delayed.
How much debt does Hyperfine, Inc. have?
Hyperfine, Inc.'s debt-to-equity ratio is 36.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Hyperfine, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Hyperfine, Inc. are Sensus Healthcare, Inc., Spectral AI, Inc., Jin Medical International Ltd., Nephros Inc and Vivos Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Hyperfine, Inc.'s.
Are insiders buying or selling Hyperfine, Inc. stock?
Over the last 12 months, Hyperfine, Inc.'s directors and officers reported 0 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Hyperfine, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Hyperfine, Inc. announces its own schedule.